Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Long- and short-term SSRI use contributes to increased hip fracture risk

07 Nov 2019

Treatment with selective serotonin reuptake inhibitors (SSRIs) in the short and long term appears to bear an increased risk of hip fracture, according to a recent study.

The case-control study used data from the US Renal Data System and included 4,912 maintenance haemodialysis patients with hip fracture and 49,120 nonfracture controls. All participants had >1 year of Medicare parts A and B coverage and >3 years of part D coverage.

During the 3-year part D coverage period, SSRI exposure was characterized as any (≥1 prescription filled), low, moderate and high use (<20 percent, 20 to <80 percent, and ≥80 percent of days covered by filled prescriptions, respectively).

On conditional logistic regression analysis, SSRI use conferred a 25-percent increase in hip fracture risk (adjusted odds ratio [OR], 1.25, 95 percent confidence interval [CI], 1.17–1.35). Risk estimates for fracture associated with any, low, moderate and high SSRI use were as follows: 1.25 (95 percent CI, 1.17–1.35), 1.20 (95 percent CI, 1.08–1.32), 1.31 (95 percent CI, 1.18–1.43) and 1.26 (95 percent CI, 1.12–1.41), respectively.

Researchers performed a separate examination of new short-term SSRI exposure in cases and controls with >18 months of part D coverage and no prior antidepressant use for 1 year. Results revealed a similar pattern of association with hip fracture risk (adjusted OR, 1.43, 95 percent CI, 1.23–1.67).

“The stronger association with new short-term use may suggest an acute mechanism potentially related to falls,” the researchers explained.

The study was limited by the inability to capture and account for biomarkers of mineral bone disorder.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.